Newsroom

Seer Proteograph™ Product Suite is being used by TruDiagnostic in an aging study designed to create a next-generation multi-omic aging clock.

Seer VP of Proteomics, Daniel Hornburg, was interviewed by Authority Magazine to discuss how the study of multi-omics in space can improve our life on earth.

Read more in Technology Networks about how profiling the plasma proteome could provide detailed insights into the health of individuals, as well as enabling earlier detection of a range of diseases.

Read more in Clinical Lab Manager on how a plasma-based biomarker discovery platform for non-small cell lung cancer was developed using Seer’s unbiased proteogenomic approach to map protein variants arising from a single gene.

Published results highlight simultaneous superior performance across depth, precision, and throughput versus conventional plasma proteomics workflows.

Seer CEO Omid Farohkzad was profiled in the San Francisco Business Times. Read more on his unique career path, what inspires him to continue making an impact in life sciences, and his vision of proteomics for the future of healthcare.

Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies.

Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program.

Researchers from the Oregon Health & Science University, the Broad Institute, Sanford Burnham Prebys Medical Discovery Institute, and proteomics software company Protein Metrics presented data and their experience using Seer’s Proteograph technology. (Premium content, sign in may be required.)

Seer Welcomes Rachel Haurwitz, Ph.D. to Board of Directors

Seer CEO Omid Farokhzad shares his perspective on how multidisciplinary approaches, including proteomics and genomics, will greatly expand our knowledge of biology and human health as part of Genetic Engineering & Biotechnology News’ 40th anniversary issue.

This article in BioCentury explains how ‘omics technologies can improve the runway to drug approvals across diverse disease areas. For mass-spectrometry-based proteomic and metabolomic measurements the ability to capture a wider range of biological complexity is a more direct reflection of a patient’s state of health. (Subscription required)

Dr. Omid Farokhzad, Chair, CEO and Founder of Seer, discusses how Seer’s cutting edge work with protein and proteomics is removing technological barriers and providing scientists with better tools to make breakthroughs than ever before. Watch the video here

BioReport Podcast: CEO Omid Farokhzad explains why, although great progress has been made in understanding the human genome, the human proteome remains relatively unexplored.

Motley Fool: interview with CEO Omid Farokhzad on the future of proteomics.

Benzinga: interview with CEO Omid Farokhzad on the importance of proteomics

Seer signs agreement with Sciex: Seer and SCIEX have signed a commercial agreement to provide end to end unbiased proteomics solutions.

Seer adds board members: Seer appoints Deep Nishar and Mostafa Ronaghi, Ph.D. to its Board of Directors

Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics

Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics

Seer announced the pricing of its initial public offering of 9,210,527 shares of Class A common stock.

Seer Appoints Catherine Friedman to its Board of Directors

Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing

Seers Announces Publication in Nature Communications Demonstrating Performance, Scalability and Utility of its Platform Technology for Deep, Unbiased Proteomics.